Sodium Phenylbutyrate Market

Sodium Phenylbutyrate market is experiencing a CAGR of 10.3 % during the forecast period, this growth is driven by the increasing prevalence of urea cycle disorders (UCDs) and other rare metabolic diseases, where sodium phenylbutyrate plays a critical therapeutic role. Additionally, its potential application in managing neurological disorders and cancer is expanding its pharmaceutical demand.

The pharmaceutical segment dominates the market by application due to sodium phenylbutyrate’s primary use in treating UCDs and other inherited metabolic disorders. Hospitals and specialty clinics represent the key end-user segment, as they are at the forefront of diagnosis and long-term treatment of these rare conditions. Meanwhile, research institutions are actively investigating newer therapeutic indications, further supporting market growth through clinical innovation.

North America leads the global Sodium Phenylbutyrate market, accounting for more than 40% of the total revenue in 2024. This is attributed to robust healthcare infrastructure, high awareness of rare diseases, and favorable reimbursement policies. The Asia-Pacific region is expected to witness the fastest growth during the forecast period, fueled by rising healthcare investments, growing awareness, and improvements in diagnostic infrastructure across India, China, and Southeast Asia.

Prominent players operating in the market include Horizon Therapeutics, Recordati Rare Diseases, Swedish Orphan Biovitrum AB (Sobi), Acer Therapeutics, Medunik USA, Dr. Reddy’s Laboratories, Sun Pharmaceuticals, and Pfizer. These companies are focusing on expanding product availability, securing regulatory approvals, and entering new markets through strategic partnerships, thereby solidifying their global presence in this niche but rapidly growing segment.